Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

Thumbnail for Study of JAK2 V617F Allele Burden by Droplet Digital PCR in BCR::ABL1-Negative Myeloproliferative Neoplasms and its Implications on Disease Phenotype

MPN - 1017

Study of JAK2 V617F Allele Burden by Droplet Digital PCR in BCR::ABL1-Negative Myeloproliferative Neoplasms and its Implications on Disease Phenotype

Shano Naseem

Poster Presenter: Shano Naseem

$Thumbnail for Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin (Mosun-Pola) Shows a Sustained Progression-Free Survival Benefit Compared With Rituximab Plus Polatuzumab Vedotin (R-Pola) in Patients With Relapsed or Refractory Large B-Cell Lymphoma After Long-Term Follow-Up$

ABCL - 568

Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin (Mosun-Pola) Shows a Sustained Progression-Free Survival Benefit Compared With Rituximab Plus Polatuzumab Vedotin (R-Pola) in Patients With Relapsed or Refractory Large B-Cell Lymphoma After Long-Term Follow-Up

L Elizabeth Budde

Poster Presenter: L Elizabeth Budde

Thumbnail for Successful Treatment of CD19+ Mixed-Phenotype Acute Leukemia With Brexucabtagene Autoleucel Plus Tyrosine Kinase Inhibitor

CT - 976

Successful Treatment of CD19+ Mixed-Phenotype Acute Leukemia With Brexucabtagene Autoleucel Plus Tyrosine Kinase Inhibitor

Molly Gallogly

Poster Presenter: Molly Gallogly

Thumbnail for Suicide Mortality Among Hematological Malignancy Survivors: A Population-Based SEER-CDC analysis

AML - 350

Suicide Mortality Among Hematological Malignancy Survivors: A Population-Based SEER-CDC analysis

Vidushi Reddy Gillela

Poster Presenter: Vidushi Reddy Gillela

Thumbnail for Superior 96-weeks MMR rates and safety with generic Dasatinib-50mg in newly diagnosed CML : Large Real-world multicentre study from India

CML - 1655

Superior 96-weeks MMR rates and safety with generic Dasatinib-50mg in newly diagnosed CML : Large Real-world multicentre study from India

Sujay Rainchwar

Poster Presenter: Sujay Rainchwar

Thumbnail for Survival and Cardiovascular Outcomes Associated With GLP-1 Receptor Agonist Exposure in Patients With Multiple Myeloma and Metabolic Comorbidities: A Propensity-Matched TriNetX Analysis

MM - 857

Survival and Cardiovascular Outcomes Associated With GLP-1 Receptor Agonist Exposure in Patients With Multiple Myeloma and Metabolic Comorbidities: A Propensity-Matched TriNetX Analysis

Nnamdi Omenuko

Poster Presenter: Nnamdi Omenuko

Thumbnail for Survival and Early Mortality Disparities in Classical Hodgkin Lymphoma Across the Immunotherapy Era: A SEER Analysis (2010-2022)

HL - 092

Survival and Early Mortality Disparities in Classical Hodgkin Lymphoma Across the Immunotherapy Era: A SEER Analysis (2010-2022)

Edward Mwarangu

Poster Presenter: Edward Mwarangu

Thumbnail for Survival and Organ Outcomes in AL Amyloidosis in the Daratumumab Era: A Propensity Score-Matched Real-World Analysis

MM - 894

Survival and Organ Outcomes in AL Amyloidosis in the Daratumumab Era: A Propensity Score-Matched Real-World Analysis

Dhriti Sood

Poster Presenter: Dhriti Sood

Thumbnail for Survival and Toxicity Outcomes With Hypomethylating Agent Plus Venetoclax vs Hypomethylating Agent Alone in Higher-Risk Myelodysplastic Syndrome: A Propensity-Matched Retrospective Cohort Study

MDS - 1311

Survival and Toxicity Outcomes With Hypomethylating Agent Plus Venetoclax vs Hypomethylating Agent Alone in Higher-Risk Myelodysplastic Syndrome: A Propensity-Matched Retrospective Cohort Study

Kumar Anmol

Poster Presenter: Kumar Anmol

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.